A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation

被引：0
|
作者：
Midori Nakagaki
Michael Barras
Cameron Curley
Jason P. Butler
Glen A. Kennedy
机构：
[1] Royal Brisbane and Women’s Hospital,Pharmacy Department, Level 1 Ned Hanlon Building
[2] The University of Queensland,Bone Marrow Transplant Unit, Level 5 Joyce Tweddell Building
[3] Royal Brisbane and Women’s Hospital,undefined
来源：
Supportive Care in Cancer | 2017年 / 25卷
关键词：
Stem cell transplantation; Antiemetics; Ondansetron; Palonosetron; Olanzapine; Nausea and vomiting;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：607 / 613
页数：6
相关论文
共 50 条
  • [41] Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study
    Suzuki, K.
    Yamanaka, T.
    Hashimoto, H.
    Shimada, Y.
    Arata, K.
    Matsui, R.
    Goto, K.
    Takiguchi, T.
    Ohyanagi, F.
    Kogure, Y.
    Nogami, N.
    Nakao, M.
    Takeda, K.
    Azuma, K.
    Nagase, S.
    Hayashi, T.
    Fujiwara, K.
    Shimada, T.
    Seki, N.
    Yamamoto, N.
    ANNALS OF ONCOLOGY, 2016, 27 (08) : 1601 - 1606
  • [42] Comparison of Ondansetron and Palonosetron on Postoperative Nausea and Vomiting in Patients Undergoing Maxillofacial Surgery: A Prospective Randomized Double-Blind Clinical Trial
    Kumar, Jitendra
    Verma, Dinesh Kumar
    Rai, Anshul J.
    Yadav, Vineeta
    Lal, Babu
    Shakti, Prateek
    JOURNAL OF MAXILLOFACIAL & ORAL SURGERY, 2023,
  • [43] Effectiveness of palonosetron versus granisetron in preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis
    Yu-Chen Hsu
    Ching-Yao Chen
    Ka-Wai Tam
    Chin-Yu Hsu
    European Journal of Clinical Pharmacology, 2021, 77 : 1597 - 1609
  • [44] Efficacy and safety of palonosetron as salvage treatment in the prevention of chemotherapy-induced nausea and vomiting in patients receiving low emetogenic chemotherapy (LEC)
    Paul J. Hesketh
    Gary Morrow
    Anna W. Komorowski
    Raza Ahmed
    David Cox
    Supportive Care in Cancer, 2012, 20 : 2633 - 2637
  • [45] A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting
    Clemons, M.
    Dranitsaris, G.
    Sienkiewicz, M.
    Sehdev, S.
    Ng, T.
    Robinson, A.
    Mates, M.
    Hsu, T.
    McGee, S.
    Freedman, O.
    Kumar, V.
    Fergusson, D.
    Hutton, B.
    Vandermeer, L.
    Hilton, J.
    BREAST, 2020, 54 : 278 - 285
  • [46] Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21
    Kim, Hyo Jung
    Shin, Sang Won
    Song, Eun-Kee
    Lee, Na-Ri
    Kim, Jun Suk
    Ahn, Jin Seok
    Yun, Hwan-Jung
    Cho, Yo-Han
    Park, Keon Uk
    Kim, Si-Young
    Jang, Joung Soon
    Kim, Sang-We
    Lee, Hyun Woo
    Lee, Se Ryeon
    Kim, Yang Soo
    Lee, Soon Nam
    Ko, Yoon Ho
    Kim, Hwa Jung
    Kang, Jin-Hyoung
    ONCOLOGIST, 2015, 20 (12) : 1440 - 1447
  • [47] Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation
    Apolito, Vincenzo
    Giaccone, Luisa
    Ferrero, Simone
    Larocca, Alessandra
    Cavallo, Federica
    Coscia, Marta
    Beggiato, Eloise
    Butera, Sara
    Martella, Federica
    Dainese, Cristina
    Cetani, Giusy
    Scaldaferri, Matilde
    Cattel, Francesco
    Boccadoro, Mario
    Ferrero, Dario
    Bruno, Benedetto
    Cerrano, Marco
    ANNALS OF HEMATOLOGY, 2020, 99 (09) : 2197 - 2199
  • [48] Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy
    Suthinee Ithimakin
    Pathra Theeratrakul
    Apirom Laocharoenkiat
    Akarin Nimmannit
    Charuwan Akewanlop
    Nopadol Soparattanapaisarn
    Sirisopa Techawattanawanna
    Krittiya Korphaisarn
    Pongwut Danchaivijitr
    Supportive Care in Cancer, 2020, 28 : 5335 - 5342
  • [49] Aprepitant plus palonosetron versus dexamethasone plus palonosetron in preventing chemotherapy- induced nausea and vomiting in patients with moderate-emetogenic chemotherapy: A randomized, open-label, phase 3 trial
    Cheng, Yi
    Wu, Zehua
    Shi, Lishuo
    Shen, Cailu
    Zhang, Jianwei
    Hu, Huabin
    Li, Weiwei
    Cai, Yue
    Xie, Xiaoyu
    Ling, Jiayu
    Zheng, Qin
    Deng, Yanhong
    ECLINICALMEDICINE, 2022, 49
  • [50] Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy
    Ithimakin, Suthinee
    Theeratrakul, Pathra
    Laocharoenkiat, Apirom
    Nimmannit, Akarin
    Akewanlop, Charuwan
    Soparattanapaisarn, Nopadol
    Techawattanawanna, Sirisopa
    Korphaisarn, Krittiya
    Danchaivijitr, Pongwut
    SUPPORTIVE CARE IN CANCER, 2020, 28 (11) : 5335 - 5342
12345